Hepatitis a impairs the function of human hepatic CYP2A6 in vivo

Toxicology

Volumn 123, Issue 3, 1997, Pages 177-184

  Pasanen, Markku ^a,b,c   Rannala, Zoja ^d   Tooming, Aivar ^d   Sotaniemi, Eero A ^b   Pelkonen, Olavi ^a   Rautio, Arja ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL AGENCY FOR MEDICINES   (Finland)

^d Rakvere Hospital   (Estonia)

Author keywords

Cytochrome P 450; Drug metabolism; Human liver; Inflammation; Liver disease

Indexed keywords

COUMARIN; CYTOCHROME P450 ISOENZYME; MELILOTUS EXTRACT; UMBELLIFERONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG METABOLISM; FEMALE; HEPATITIS A; HUMAN; LIVER FUNCTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; URINARY EXCRETION;

ADOLESCENT; ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS A; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIXED FUNCTION OXYGENASES; TRANSAMINASES; UMBELLIFERONES;

EID: 0030761492     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(97)00119-4     Document Type: Article

References (32)

1. Bullock P., Gemzik B., Johnson D., Thomas P., Parkinson A. Evidence from dwarf rats that growth hormone may not regulate the sexual differentiation of liver cytochrome P-450 enzymes and steroid 5-alpha-reductase. Proc. Natl. Acad. Sci. USA. 88:1991;5227-5231.
2. Burnett D.A., Barak A.J., Tuma D.J., Sorrell M.F. Altered elimination of antipyrine in patients with acute viral hepatitis. Gut. 17:1976;341-344.
3. Casley-Smith, J.R., Casley-Smith, J.R., 1986. High-Protein Oedemas and the Benzo-Pyrones. J.B. Lippincott, Sydney.
4. Chemin I., Takahashi S., Bellock C., Lang M.A., Ando K., Guidotti L.G., Chisari F.V., Wild C.P. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model for fulminant hepatitis. Hepatology. 24:1996;649-656.
5. Cholerton S., Idle M.E., Vas A., Gonzalez F.J., Idle J.R. Comparison of a novel thin-layer chromatographic fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J. Chromatogr. 575:1992;325-330.
6. Cohen A.J. Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Cosmet. Toxicol. 17:1979;277-289.
7. Farber, E., Phillips, M.J., Kaufman, N., 1987. Pathogenesis of Liver Diseases. Williams and Wilkins, Los Angeles.
8. Farrell G.C., Cooksley W.G.E., Hart P., Powell L.W. Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology. 75:1978;580-588.
9. Fernandez-Salguero P., Hoffman S., Cholerton S., Mohrenweiser H., Raunio H., Rautio A., Pelkonen O., Huang J.-D., Evans W., Idle J., Gonzalez F. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet. 57:1995;651-660.
10. Hakkola J., Pasanen M., Purkunen R., Saarikoski S., Pelkonen O., Mäenpää J., Rane A., Raunio H. Expression of xenobiotic-metabolizing cytochrome P-450 forms in human adult and fetal liver. Biochem. Pharmacol. 48:1994;59-64.
11. Iscan M., Rostami H., Iscan M., Güray T., Pelonen O., Rautio A. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol. 47:1994;315-318.
12. Juvonen R.O., Autio S., Lang M.A. Pyrazole as a modifier of liver microsomal monooxygenase in DBA/2N and AKR/J mice. Biochem. Pharmacol. 36:1987;3993-3997.
13. Kiivet R.A., Svensson J.O., Bertilsson L., Sjöqvist F. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians. Pharmacol. Toxicol. 72:1993;113-115.
14. Kimonen T., Juvonen R., Alhava E., Pasanen M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol. 114:1995;832-836.
15. Kimonen T., Pasanen M., Gynther J., Poso A., Järvinen T., Alhava E., Juvonen R. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. Br. J. Pharmacol. 116:1995;2625-2630.
16. Kirby G.M., Pelkonen P., Vatanasapt V., Camus A.-M., Wild C.P., Lang M.A. Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P-450 and carcinogen metabolism in male hamster liver. Mol. Carcinog. 11:1994;81-89.
17. Kobliakov V., Popova N., Rossi L. Regulation of the expression of the sex-specific isoforms of cytochrome P-450 in rat liver. Eur. J. Biochem. 195:1991;585-591.
18. Mäenpää J., Rane A., Raunio H., Honkakoski P., Pelkonen O. Cytochrome P-450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse. Biochem. Pharmacol. 45:1993;899-907.
19. Mäenpää J., Sigusch H., Raunio H., Syngelmä T., Vuorela P., Vuorela H., Pelkonen O. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45:1993;1035-1042.
20. Matsunaga T., Nagata K., Holsztynska E.J., Lapenson D.P., Smith A., Kato R., Gelboin H.V., Waxman D.J., Gonzalez F.J. Gene conversion and differential regulation in the rat P-450 IIA gene subfamily. Purification, catalytic activity, cDNA and deduced amino acid sequence, and regulation of an adult male-specific hepatic testosterone 15-α-hydroxylase. J. Biol. Chem. 263:1988;17995-18002.
21. Pellinen P., Stenbäck F., Rautio A., Pelkonen O., Lang M., Pasanen M. Mouse liver coumarin 7-hydroxylase is exceptional in its response to hepatotoxicants: comparison to other monooxygenases. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;435-443.
22. Pellinen P., Stenbäck F., Raunio H., Pelkonen O., Pasanen M. Modification of hepatic cytochrome P-450 profile by cocaine-induced hepatotoxicity in DBA/2 mice. Eur. J. Pharmacol. - Environ. Toxicol. Pharmacol. Sect. 292:1994;57-65.
23. Pellinen P., Stenbäck F., Kojo A., Honkakoski P., Gelboin H.V., Pasanen M. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 23:1996;515-523.
24. Rautio A., Kraul H., Kojo A., Salmela E., Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics. 2:1992;227-233.
25. Renton K.W., Knickle L.C. Regulation of hepatic cytochrome P-450 during infectious disease. Can. J. Physiol. Pharmacol. 68:1990;777-781.
26. Shedlofsky S.I., Israel B.C., McClain C.J., Hill D.B., Blouin R.A. Endotoxin administration to humans inhibits hepatic cytochrome P-450-mediated drug metabolism. J. Clin. Invest. 94:1994;2209-2214.
27. Sherlock, S., 1985. Virus hepatitis. In: Diseases in the Liver and Biliary System, 7th ed. Alden Press, Oxford, Ch. 15, pp. 251-279.
28. Sotaniemi E.A., Rautio A., Bäckström M., Arvela P., Pelkonen O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br. J. Clin. Pharmacol. 39:1995;71-76.
29. Williams R.L., Blaschke T.F., Meffin P.J., Melmon K.L., Rowland M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green. Clin. Pharmacol. Ther. 30:1976;290-299.
30. Wong J.Y.Y., Lee E.J.D., Moochhala S.M. The effects of an interferon inducer, polyriboinosinic polyribocytidylic acid on cytochrome P-450 dependent hepatic progesterone metabolism. Life Sci. 53:1993;1893-1901.
31. Wright K., Morgan E.T. Regulation of cytochrome P-450 II2C12 expression by interleukin-1α, interleukin-6, and dexamethasone. Mol. Pharmacol. 39:1991;468-474.
32. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.